The earnings call highlighted strong revenue growth and improved cash flow, driven by the success of LUPKYNIS and operational efficiencies. However, challenges include a decline in gross margin and increased costs related to restructuring. The overall sentiment is balanced with significant achievements and notable challenges.

Company Guidance

During the Aurinia Pharmaceuticals earnings call, significant guidance was provided for the year ahead, highlighting key financial metrics and strategic plans. For the fourth quarter of 2024, Aurinia reported total revenue of $59.9 million, a 33% increase from the same period in 2023, while full-year revenue reached $235.1 million, marking a 34% increase year-over-year. Net product sales of LUPKYNIS also saw substantial growth, with $57.6 million in the fourth quarter, up 36% compared to the previous year, and $216.2 million for the full year, representing a 36% increase. Cash flow from operations was notably positive, with $30.1 million generated in Q4 and $44.4 million for the full year, a significant turnaround from a cash outflow of $33.5 million in 2023. Aurinia ended the year with $358.5 million in cash and investments. Looking forward, the company projects total revenue for 2025 to be between $250 million and $260 million, with net product sales ranging from $240 million to $250 million. These projections are supported by strategic initiatives, including expanding the market penetration of LUPKYNIS, leveraging new lupus nephritis treatment guidelines, and advancing the AUR200 pipeline with expected Phase 1 results in the second quarter of 2025.

Significant Revenue Growth

For the fourth quarter of 2024, total revenue was $59.9 million, up 33% from $45.1 million in the same period of 2023. For the full-year 2024, total revenue was $235.1 million, up 34% from $175.5 million in 2023.

Record Net Product Sales of LUPKYNIS

In the fourth quarter of 2024, net product sales of LUPKYNIS were $57.6 million, up 36% compared to $42.3 million in the same period of 2023. For the full-year of 2024, net product sales were $216.2 million, up 36% from $158.5 million in 2023.

Improved Cash Flow

For the year ended December 31, 2024, cash flow generated from operations was $44.4 million, compared to cash flow used in operations of $33.5 million in 2023.

Strategic Positioning and Future Projections

Aurinia expects total revenue for 2025 in the range of $250 million to $260 million and net product sales in the range of $240 million to $250 million.

---

Aurinia Pharmaceuticals (AUPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AUPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 01, 2025	2025 (Q1)	0.10 / -	-0.07	―	―	―
Feb 27, 2025	2024 (Q4)	-0.02 / 0.01	-0.19	105.26% (+0.20)	―
Nov 07, 2024	2024 (Q3)	0.01 / 0.10	-0.09	211.11% (+0.19)	―
Aug 01, 2024	2024 (Q2)	<0.01 / 0.01	-0.08	112.50% (+0.09)	―
May 02, 2024	2024 (Q1)	-0.14 / -0.07	-0.18	61.11% (+0.11)	―
Feb 15, 2024	2023 (Q4)	-0.16 / -0.19	-0.18	-5.56% (-0.01)	―
Nov 02, 2023	2023 (Q3)	-0.17 / -0.09	-0.06	-50.00% (-0.03)	―
Aug 03, 2023	2023 (Q2)	-0.18 / -0.08	-0.25	68.00% (+0.17)	―
May 04, 2023	2023 (Q1)	-0.22 / -0.18	-0.27	33.33% (+0.09)	―
Feb 28, 2023	2022 (Q4)	-0.27 / -0.18	-0.25	28.00% (+0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

AUPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 27, 2025	$7.95	$7.55	-5.03%
Nov 07, 2024	$7.52	$8.34	+10.90%
Aug 01, 2024	$5.88	$5.61	-4.59%
May 02, 2024	$5.20	$5.17	-0.58%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---